Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04338919
Other study ID # Optimized-APT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 14, 2020
Est. completion date April 1, 2023

Study information

Verified date May 2020
Source Fujian Medical University
Contact Chen Lianglong, MD, PhD
Phone +86-13950303022
Email lianglongchen@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is to evaluate the effect of optimized 12-month step-down antiplatelet therapy (APT) compared with standard 12-month dual antiplatelet therapy in clinical net adverse events, cardiovascular and cerebrovascular adverse events and reducing clinical related bleeding events in the patients with acute coronary syndrome (ACS) who are not the predominant coronary artery disease after percutaneous coronary intervention (PCI).


Description:

This is a prospective, multi- center, randomized, parallel-group trial designed to evaluate the effect of optimized 12-month step-down antiplatelet therapy compared with standard 12-month dual antiplatelet therapy in clinical net adverse clinical events, cardiovascular and cerebrovascular adverse events and reducing clinical related bleeding events in the patients with acute coronary syndrome who are not the main coronary artery disease.2020 subjects will be enrolled. After PCI,eligible patients will be randomly assigned in a 1:1 ratio to either the optimized antiplatelet therapy group(O-APT)or the standard antiplatelet therapy group(S-APT). The primary efficacy end points are clinical net adverse clinical events ,or the event rate of the composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, ischemia driven coronary revascularization and stroke at 12 months. The primary safety end point is the incidence of PLATO major bleeding or Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding at 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 2020
Est. completion date April 1, 2023
Est. primary completion date April 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients admission for coronary artery disease treatment with non-emergency percutaneous intervention with stent deployment

- Enrollment into the study will require meeting at least one of these clinical syndromes.

1. Unstable angina

2. Non-ST elevation myocardial infarction (NSTEMI)

3. ST elevation MI (STEMI)

- Non predominant coronary artery disease, it is defined as: exclusion of left main artery disease or left main artery bifurcated disease or ostial left anterior descending disease by coronary angiography imaging, and other high-risk vascular diseases considered by surgeons

- Patients understands the study requirements and the treatment procedures and provided informed consent before the procedure

Exclusion Criteria:

- Complications during stenting for coronary artery disease

- Stroke within 3 months or any permanent neurologic deficit, and prior intracranial bleed, or any intracranial disease such as aneurysm or fistula

- Any planned surgery within 6 months

- any reason why any antiplatelet therapy might need to be discontinued within 12 months

- Severe chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) < 15ml/min/1.73m^2

- Need for chronic oral anticoagulation (warfarin/coumadin or direct oral anticoagulants)

- Platelet count < 100,000 mm^3

- Contraindication to aspirin

- Contraindication to ticagrelor

- Liver cirrhosis

- Women of child-bearing potential

- Life expectancy < 1 year

- Any condition likely to interfere with study processes including medication compliance or follow-up visits (e.g. dementia, alcohol abuse, severe frailty, long distance to travel for follow-up visits, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Percutaneous coronary intervention
PCI with stent implantation
Drug:
Ticagrelor plus aspirin
Ticagrelor plus aspirin

Locations

Country Name City State
China Department of Cardiology, Union Hospital, Fujian Medical University Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other PLATO-defined any minor bleeding event To compare two intensities of ticagrelor therapy on minor bleeding event as any bleeding requiring medical intervention but not meeting the criteria for major bleeding. Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Other PLATO-defined any minimal bleeding event To compare two intensities of ticagrelor therapy on minimal bleeding event as all other bleeding(eg, bruising, bleeding gums, oozing from injection site) not requiring intervention or treatment.Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Other Other adverse events To compare two intensities of ticagrelor therapy on other adverse events including dyspnea or bradyarrhythmia. Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Other Increase of serum uric acid or creatinine To compare two intensities of ticagrelor therapy on increase of serum uric acid or creatinine.Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Primary Major cardiovascular and cerebrovascular adverse events Participants with death from cardiovascular causes, non-fatal myocardial infarction, stent thrombosis,Ischemia driven coronary revascularization and ischemic stroke.Intention to treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. Up to 12 months after PCI
Primary Major bleeding events Plato massive hemorrhage events, including fatal hemorrhage, intracranial hemorrhage, pericardial hemorrhage with pericardial tamponade, hypovolemic shock or severe hypotension caused by hemorrhage, requiring pressor or surgery, hemoglobin level dropping 5.0 g or more per deciliter, or at least requiring blood transfusion. Events were adjudicated by an endpoint committee.
BARC type 2, 3 or 5 bleeding. Events were adjudicated by an endpoint committee.
Up to 12 months after PCI
Primary The net adverse clinical events included major adverse cardiovascular and cerebrovascular events or major bleeding events. Up to 12 months after PCI
Secondary Participants with myocardial infarction (MI) event. Number of participants with MI event. Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Secondary Participants with death from cardiovascular causes. Number of participants with death from cardiovascular causes. Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Secondary Participants with death from any cause. Number of participants with death from any cause. Events were adjudicated by an endpoint committee. Up to 36 months after PCI
Secondary PLATO-defined any bleeding event. Number of participants with any other bleeding events (minor bleeding or minimal bleeding) as defined by the PLATO. Events were adjudicated by an endpoint committee. Up to 36 months after PCI
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study